- Oral presentation
- Open Access
Assessment of tumour resection margins using optical coherence tomography
© Hamdoon et al; licensee BioMed Central Ltd. 2010
- Published: 29 October 2010
- Optical Coherence Tomography
- Resection Margin
- Local Resection
- Membrane Organisation
- Negative Resection Margin
In the treatment of cancer, the fundamental surgical goal is to remove all local malignant disease and leave no residual malignant cells. Studies have demonstrated the benefit of achieving negative resection margins in terms of disease free local recurrence and overall survival. The surgical margins for head & neck cancer may vary widely depending on the site of disease.
Optical coherence tomography (OCT) is an imaging modality that uses light to determine cross-sectional anatomy in turbid media such as living tissues.
In this study, we used this technology to evaluate resection margins acquired from patients with oral squamous cell cancer (OSCC).
Twenty-five patients with newly diagnosed T1-T2 OSCC underwent local resection. In the immediate ex-vivo phase, OCT was used to interrogate the surgical margins of these specimens and the results were, then, compared to histopathology. Inter, Intra-observer differences, sensitivity and specificity was calculated.
The junctional epithelium (between positive and negative margins) can be identified by gradual change in epithelial thickness and basement membrane organisation (integrity) from the normal to pathological. Identified changes in tumour positive margins include hyperkeratinisation, breach of the basement membrane and disorganised epithelial structure. Tumour spread pattern could be identified on the majority of the interrogated tissue. Sensitivity and specificity were calculated and proved to be encouraging.
The results from this study are encouraging and suggest the feasibility of using OCT in differentiating between positive and negative surgical margins.
We would like to thank the BAOMS for supporting this research project.
This article is published under license to BioMed Central Ltd.